Contact Us
Drug Search Results
More Filters [+]

TBA-7371

Alternative Names: tba-7371, tba7371, tba 7371
Latest Update: 2024-04-11
Latest Update Note: Clinical Trial Update

Product Description

TBA-7371 is an antimicrobial compound developed by TB Alliance inÊcollaboration with AstraZeneca. It is in a novel class of drugs known as DprE1 inhibitors, of which there are two other compounds in early development. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.Ê (Sourced from: https://www.tballiance.org/news/tb-alliance-moves-two-novel-tuberculosis-drugs-human-trials)

Mechanisms of Action: DprE1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bill & Melinda Gates Medical Research Institute
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TBA-7371

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Tuberculosis, Pulmonary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Gates MRI-TBD03-201

P2

Completed

Tuberculosis, Pulmonary

2022-10-05

TBA-7371-CL001

P1

Completed

Tuberculosis, Pulmonary

2018-07-08

Recent News Events

Date

Type

Title

04/03/2024

PubMed

 Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.

02/08/2024

PubMed

 Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis.

03/16/2023

PubMed

 Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions